
The withdrawal came on the eve of a Senate committee vote, leaving the FDA without a nominee as vaccine and mifepristone debates continue.
A protease inhibitor (PI) that circumvents the problems of earlier PIs such as certain adverse events, a complex dosing regimen, and toxicities such as lipid disturbances and glucose metabolism will soon be available to those infected with HIV. The FDA recently approved atazanavir (Reyataz, Bristol-Myers Squibb) for use in combination with other antiretroviral agents for the treatment of HIV infection. Atazanavir will be available in pharmacies sometime this month.






